While resistance to gemcitabine was associated with both RRM1 and RRM2 overexpression [17], [56], small interfering RNA targeting the RRM2 catalytic subunit, reported in [57], enhanced the chemosensitivity to gemcitabine of pancreatic adenocarcinoma in vitro and in vivo. Here, RRM1 is linked to pancreatic adenocarcinoma.